Eguchi, T.; Ono, K.; Calderwood, S.; Okamoto, K. Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition. Preprints2019, 2019120386. https://doi.org/10.20944/preprints201912.0386.v1
APA Style
Eguchi, T., Ono, K., Calderwood, S., & Okamoto, K. (2019). Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition. Preprints. https://doi.org/10.20944/preprints201912.0386.v1
Chicago/Turabian Style
Eguchi, T., Stuart Calderwood and Kuniaki Okamoto. 2019 "Exosome Release of Drugs: Coupling with Epithelial-Mesenchymal Transition" Preprints. https://doi.org/10.20944/preprints201912.0386.v1
Abstract
Extracellular vesicles (EVs), such as exosomes or oncosomes are released with molecules unfavorable for survival from cells. In addition, accumulating evidence has shown that tumor cells often eject anti-cancer drugs such as chemotherapeutics and targeted drugs within EVs, a novel mechanism of drug resistance. The EV-releasing, drug resistance phenotype is often coupled with cellular dedifferentiation and transformation, cells undergoing epithelial-mesenchymal transition (EMT) and taking on a cancer stem cell phenotype. Recent studies have shown that the release of EVs is also involved in immunosuppression. The concept of the resistance-associated secretory phenotype (RASP) is reviewed herein.
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.